Published in Life Sci on January 01, 1998
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol (2009) 1.08
Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol (2000) 1.07
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol (2009) 1.05
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl) (2010) 1.02
Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) (2013) 0.97
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol (2012) 0.94
The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol (2005) 0.93
Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci (2011) 0.91
The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology (Berl) (2014) 0.90
Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats. Psychopharmacology (Berl) (2009) 0.87
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl) (2015) 0.81
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem (2014) 0.81
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One (2014) 0.80
Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats. Br J Pharmacol (2015) 0.80
Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. Br J Pharmacol (2016) 0.79
Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys. Psychopharmacology (Berl) (2007) 0.78
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Front Pharmacol (2016) 0.78
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry (2016) 0.77
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. Psychopharmacology (Berl) (2016) 0.76
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol (2017) 0.75
Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J Pharmacol Exp Ther (2016) 0.75
Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychol Med (2016) 0.75
Clinical and Pre-Clinical Evidence for Functional Interactions of Cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology (2017) 0.75
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 11.96
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 4.31
Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther (1986) 2.30
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther (1988) 2.29
Microdialysis measurement of cortical and hippocampal acetylcholine release during sleep-wake cycle in freely moving cats. Brain Res (1995) 1.90
Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol (1986) 1.73
Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience (1989) 1.49
Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res (2001) 1.46
Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci (1985) 1.31
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci U S A (1993) 1.25
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol (1999) 1.19
Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sci (1984) 1.08
Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol (1985) 1.05
Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem (1983) 1.03
Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann N Y Acad Sci (1986) 1.00
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci (1983) 1.00
Impaired long-term potentiation induction in dentate gyrus of calretinin-deficient mice. Proc Natl Acad Sci U S A (1997) 0.99
Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart. Life Sci (1985) 0.98
Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience (2000) 0.94
Cannabinoid penetration into mouse brain as determined by ex vivo binding. Eur J Pharmacol (1999) 0.93
Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res (1991) 0.91
Photoaffinity labeling of peripheral-type benzodiazepine-binding sites. Mol Pharmacol (1987) 0.89
Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport (1998) 0.88
Chronic ethanol consumption in rats: correlation between memory performance and hippocampal acetylcholine release in vivo. Neuroscience (1996) 0.88
Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol (1999) 0.88
Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl) (1989) 0.86
Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Biochem Pharmacol (1997) 0.86
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci (2000) 0.85
Opposite effects of an agonist, RO5-4864, and an antagonist, PK 11195, of the peripheral type benzodiazepine binding sites on audiogenic seizures in DBA/2J mice. Life Sci (1984) 0.85
PK 11195, an antagonist of peripheral benzodiazepine receptors, reduces ventricular arrhythmias during myocardial ischemia and reperfusion in the dog. Eur J Pharmacol (1985) 0.85
Hemisynaptic distribution patterns of presenilins and beta-APP isoforms in the rodent cerebellum and hippocampus. Synapse (2000) 0.85
"Peripheral type" benzodiazepine binding sites in rat adrenals: binding studies with [3H]PK 11195 and autoradiographic localization. Arch Int Pharmacodyn Ther (1983) 0.84
Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol (1994) 0.84
Opposite effects of two ligands for peripheral type benzodiazepine binding sites, PK 11195 and RO5-4864, in a conflict situation in the rat. Life Sci (1985) 0.84
The central cholinergic system has a role in the antinociception induced in rodents and guinea pigs by the antimigraine drug sumatriptan. J Pharmacol Exp Ther (1996) 0.84
Automated brain dialysis of acetylcholine in freely moving rats: detection of basal acetylcholine. Life Sci (1987) 0.83
Veillonellae: personal observation of a fatal bacteremia. Boll Ist Sieroter Milan (1989) 0.83
Characterization of peripheral type benzodiazepine binding sites in human and rat platelets by using [3H]PK 11195. Studies in hypertensive patients. Biochem Pharmacol (1984) 0.82
The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol (2000) 0.82
Partial purification and pharmacology of peripheral-type benzodiazepine receptors. J Recept Res (1987) 0.81
Immunohistochemical analysis of presenilin-1 expression in the mouse brain. FEBS Lett (1996) 0.81
Non-DA prefronto-cortical efferents modulate D1 receptors in the nucleus accumbens. Brain Res (1984) 0.81
Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole. J Pharm Pharmacol (1998) 0.80
Pharmacology of peripheral type benzodiazepine receptors in the heart. Prog Clin Biol Res (1985) 0.80
Stereoselective inhibition of the binding of [3H]PK 11195 to peripheral-type benzodiazepine binding sites by a quinolinepropanamide derivative. Eur J Pharmacol (1986) 0.80
Immunohistochemical analysis of presenilin 2 expression in the mouse brain: distribution pattern and co-localization with presenilin 1 protein. Brain Res (1997) 0.80
Proteolytical processing of mutated human amyloid precursor protein in transgenic mice. Brain Res Mol Brain Res (1997) 0.80
RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J Pharmacol Exp Ther (1995) 0.80
Enoxaparin reduces cerebral edemaafter photothrombotic injury in the rat. Haemostasis (1999) 0.79
In vivo labelling in several rat tissues of 'peripheral type' benzodiazepine binding sites. Eur J Pharmacol (1984) 0.79
Distinct properties of cholecystokinin-8 and mixed dopamine-cholecystokinin-8 neurons innervating the nucleus accumbens. Ann N Y Acad Sci (1985) 0.79
Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci U S A (1988) 0.79
Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides (1989) 0.79
Pharmacological properties and mechanism of action of the cyclopyrrolones. Encephale (1993) 0.79
The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull (1989) 0.79
Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats. Eur J Pharmacol (1997) 0.78
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology (2000) 0.78
Role of dorsal mesencephalic reticular formation and deep layers of superior colliculus as out-put stations for turning behaviour elicited from the substantia nigra pars reticulata. Brain Res (1981) 0.78
Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. Bioorg Med Chem Lett (1999) 0.78
The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann N Y Acad Sci (1994) 0.78
Modulation of basal and stress-induced release of acetylcholine and dopamine in rat brain by abecarnil and imidazenil, two anxioselective gamma-aminobutyric acidA receptor modulators. J Pharmacol Exp Ther (1995) 0.78
Effects of ebselen, a glutathione peroxidase mimic, in several models of mitochondrial dysfunction. Ann N Y Acad Sci (1999) 0.78
Histidine modification with diethylpyrocarbonate induces a decrease in the binding of an antagonist, PK 11195, but not of an agonist, RO5-4864, of the peripheral benzodiazepine receptors. Life Sci (1984) 0.77
Prognostic significance of Lewis y antigen in resected stage I and II non-small cell lung cancer. Chest (1998) 0.77
The effect of riluzole and mannitol on cerebral oedema after cryogenic injury in the mouse. Neurosci Lett (1999) 0.77
Autoradiographic localization of peripheral benzodiazepine binding sites in the cat brain with [3H]PK 11195. Brain Res Bull (1984) 0.77
Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV. Ann Ital Med Int (2000) 0.77
A re-evaluation of the role of superior colliculus in turning behaviour. Brain Res (1982) 0.77
L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eur J Pharmacol (1992) 0.77
Axonal transport of dopamine-containing vesicles labelled in vivo with [3H]reserpine. Eur J Neurosci (1993) 0.76
Role of substantia nigra pars reticulata neurons in the expression of neuroleptic-induced catalepsy. Brain Res (1981) 0.76
Rapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats. J Pharmacol Exp Ther (1985) 0.76
Opposite effects of sulfated cholecystokinin on DA-sensitive adenylate cyclase in two areas of the rat nucleus accumbens. Eur J Pharmacol (1986) 0.75
Behavioural effects of GABA-agonists and antagonists infused in the mesencephalic reticular formation - deep layers of superior colliculus. Brain Res (1981) 0.75
Role of dorsal mesencephalic reticular formation and deep layers of superior colliculus in turning behaviour elicited from the striatum. Brain Res (1981) 0.75
Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem (2000) 0.75
Motor and postural effects of kainic acid or GABA agonist and antagonist injection into the cerebellar nucleus fastigii. Birth Defects Orig Artic Ser (1983) 0.75
Pharmacological evidence that PK 8165 behaves as a partial agonist of brain type benzodiazepine receptors. Arch Int Pharmacodyn Ther (1984) 0.75
The 5-hydroxytryptamine-releasing properties of two epimer quinoline derivatives. Neuropharmacology (1984) 0.75
[Motor and postural effects in intracerebellar injection of kainic acid: possible role of the bulbar reticular formation]. Boll Soc Ital Biol Sper (1983) 0.75
A phase II study of oral fluorouracil for gastrointestinal cancer. Anticancer Drugs (1996) 0.75
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg Med Chem Lett (2000) 0.75
8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists. Bioorg Med Chem (2000) 0.75
Effects of RPR 118723, a novel antagonist at the glycine site of the NMDA receptor, in vitro. Eur J Pharmacol (2000) 0.75
8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg Med Chem Lett (2000) 0.75
Modulation of voltage-operated, but not receptor-operated, calcium channels in the rabbit aorta by PK 11195, an antagonist of peripheral-type benzodiazepine receptors. J Cardiovasc Pharmacol (1986) 0.75
[Interaction between viruses and basic substances. I. Effect of methyl-lysozyme on influenza virus: infecting and antigenic activity of the complexes]. Ig Mod (1966) 0.75
Role of GABA neurons in the expression of striatal motor functions. Adv Biochem Psychopharmacol (1981) 0.75
Fastigial influences on postural tonus as studied by kainate lesions and by local infusion of GABAergic drugs in the rat. Brain Res (1984) 0.75
Ordered disorder in the aged brain. Adv Exp Med Biol (1991) 0.75
Decreased surface antigen density on lymphocytes of elderly humans. Ann Ital Med Int (2000) 0.75
A new pharmacological approach to the facilitation of acetylcholine transmission. Clin Neuropharmacol (1992) 0.75
Effect of barbiturates and benzodiazepines on local kainate toxicity in the striatum and in the retina. Adv Biochem Psychopharmacol (1981) 0.75